All adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
1 finding from 1 review
All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Infections (All) compared with no bortezomib (moderate certainty).
1 finding from 1 review
All adverse events – not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in adverse events: all grade by week 8 compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
2 findings from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review